Dose-response of hyaluronate-based viscoelastic hydrogels for the treatment of knee osteoarthrosis: a prospective, randomized, comparative clinical trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F20%3AN0000023" target="_blank" >RIV/00023728:_____/20:N0000023 - isvavai.cz</a>
Result on the web
<a href="https://www.minervamedica.it/en/journals/minerva-orthopedics/article.php?cod=R14Y2020N02A0045" target="_blank" >https://www.minervamedica.it/en/journals/minerva-orthopedics/article.php?cod=R14Y2020N02A0045</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.23736/S0394-3410.20.03967-3" target="_blank" >10.23736/S0394-3410.20.03967-3</a>
Alternative languages
Result language
angličtina
Original language name
Dose-response of hyaluronate-based viscoelastic hydrogels for the treatment of knee osteoarthrosis: a prospective, randomized, comparative clinical trial
Original language description
A hyaluronate formulation for viscosupplementation, Hymovis (HYADD 4) has been proposed for treating osteoarthritis (OA) through a single injection instead of two. This study aimed to compare the safety and performance of two different doses of a single Hymovis injection to those of Synvisc-One, a well-known single-injection formulation. ixty OA patients were prospectively recruited and randomly assigned to a single injection of Hymovis 4 mL/32mg (N.=20, age 63 +/- 9 years) or 6 mL/48 mg (N.=22, age 67 +/- 8 years), or Synvisc-One 6 mL/48 mg (N.=20, age 64 +/- 10 years), and assessed through the Western Ontario McMaster University Osteoarthritis index (WOMAC) on a monthly basis up to 6 months. Two patients treated with Synvisc-One withdrew due to injection site joint inflammation. A significant improvement in OA symptoms was observed for all study groups at all time points following injection. No significant differences were observed among the treatment groups for all the study performance and safety endpoints. One injection of Hymovis 4 mL/32 mg was as safe and effective as one injection of Synvisc-One 6 mL/48 mg and should be the preferred dosage in the treatment of symptomatic knee OA by single intra-articular injection.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30226 - Rheumatology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
MINERVA ORTOPEDICA E TRAUMATOLOGICA
ISSN
0026-4911
e-ISSN
1827-1707
Volume of the periodical
71
Issue of the periodical within the volume
2
Country of publishing house
IT - ITALY
Number of pages
11
Pages from-to
45-55
UT code for WoS article
000570207600002
EID of the result in the Scopus database
2-s2.0-85084213859